Sign in or Register   Sign in or Register
  |  

Mouse Anti-BCOR Recombinant Antibody (CBYY-0453) (CBMAB-0456-YY)

This product is mouse antibody that recognizes BCOR. The antibody CBYY-0453 can be used for immunoassay techniques such as: WB, IP, IF, ELISA
See all BCOR antibodies
Published Data
Mouse Anti-BCOR Recombinant Antibody (CBYY-0453) (CBMAB-0456-YY) in IHC
a BCOR staining of the intra-abdominal tumor. b BCOR staining of uterine adenosarcoma cells. ...View More
Hasegawa, C., Washimi, K., Hiroshima, Y., Kasajima, R., Kikuchi, K., Notomi, T., ... & Yokose, T. (2023). Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling. Diagnostic Pathology, 18(1), 1-7.
Mouse Anti-BCOR Recombinant Antibody (CBYY-0453) (CBMAB-0456-YY) in IHC
Immunohistochemical features of CNS embryonal tumors with PLAGL gene amplifcation. Shown are representative immunostains of a a PLAGL2-amplifed tumor in a 1-year-old female patient and b a PLAGL1-amplifed tumor in a 13-year-old female patient. ...View More
Keck, M. K., Sill, M., Wittmann, A., Joshi, P., Stichel, D., Beck, P., ... & Jones, D. T. (2023). Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. Acta neuropathologica, 145(1), 49-69.
Mouse Anti-BCOR Recombinant Antibody (CBYY-0453) (CBMAB-0456-YY) in WB
PCGF1 gene expression (DESeq2-normalized counts) in the indicated cell lines (mean ± SD; top). Bottom, corresponding Western blot analysis of nuclear extracts. RNA-seq, RNA sequencing; Tr, PUFD-truncated. ...View More
Schaefer, E. J., Wang, H. C., Karp, H. Q., Meyer, C. A., Cejas, P., Gearhart, M. D., ... & Lindsley, R. C. (2022). BCOR and BCORL1 mutations drive epigenetic reprogramming and oncogenic signaling by unlinking PRC1. 1 from target genes. Blood cancer discovery, 3(2), 116-135.
Mouse Anti-BCOR Recombinant Antibody (CBYY-0453) (CBMAB-0456-YY) in WB
Western blot analysis of nuclear extracts from WT or PCGF1KO K562 cells. PCGF1 mutations are illustrated in the schematic (bottom). KO1, p.I60fs*; KO2, p.I60fs*/p.Y163fs*; KO3, p.Y163del. ...View More
Schaefer, E. J., Wang, H. C., Karp, H. Q., Meyer, C. A., Cejas, P., Gearhart, M. D., ... & Lindsley, R. C. (2022). BCOR and BCORL1 mutations drive epigenetic reprogramming and oncogenic signaling by unlinking PRC1. 1 from target genes. Blood cancer discovery, 3(2), 116-135.

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-0453
Antibody Isotype
IgG1, κ
Application
WB, IP, IF, ELISA

Basic Information

Immunogen
Amino acids 1-300 mapping at the N-terminus of BCoR of human origin.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG1, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500
ELISA1:100-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, 0.1% gelatin
Preservative
< 0.1% sodium azide
Concentration
0.2 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
BCL6 Corepressor
Introduction
The protein encoded by this gene was identified as an interacting corepressor of BCL6, a POZ/zinc finger transcription repressor that is required for germinal center formation and may influence apoptosis. This protein selectively interacts with the POZ domain of BCL6, but not with eight other POZ proteins. Specific class I and II histone deacetylases (HDACs) have been shown to interact with this protein, which suggests a possible link between the two classes of HDACs. Several transcript variants encoding different isoforMouse have been found for this gene. A pseudogene of this gene is found on chromosome Y.
Entrez Gene ID
54880
UniProt ID
Q6W2J9
Alternative Names
BCL6 Corepressor; BCL-6 Interacting Corepressor; BCL6 Co-Repressor; BCL-6 Corepressor; KIAA1575; MCOPS2; ANOP2; MAA2; BCoR;
Function
Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2).
Biological Process
Blastocyst hatching Source: Ensembl
Heart development Source: UniProtKB
Histone H2A monoubiquitination Source: UniProtKB
Negative regulation of bone mineralization Source: UniProtKB
Negative regulation of histone H3-K36 methylation Source: UniProtKB
Negative regulation of histone H3-K4 methylation Source: UniProtKB
Negative regulation of tooth mineralization Source: UniProtKB
Negative regulation of transcription, DNA-templated Source: UniProtKB
Negative regulation of transcription by RNA polymerase II Source: UniProtKB
Odontogenesis Source: UniProtKB
Roof of mouth development Source: UniProtKB
Specification of axis polarity Source: UniProtKB
Cellular Location
Nucleus
Involvement in disease
Microphthalmia, syndromic, 2 (MCOPS2): A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.

Ishi, Y., Shimizu, A., Takakuwa, E., Sugiyama, M., Okamoto, M., Motegi, H., ... & Yamaguchi, S. (2021). High‐grade neuroepithelial tumor with BCL6 corepressor‐alteration presenting pathological and radiological calcification: A case report. Pathology International, 71(5), 348-354.

Mardi, L., Tauziède‐Espariat, A., Guillemot, D., Pierron, G., Gigant, P., Mehdi, L., ... & Varlet, P. (2021). Bcor Immunohistochemistry, And Not SATB2, Is A Sensitive And Specific Diagnostic Biomarker For Cns Tumors With BCOR Internal Tandem Duplication. Histopathology.

Li, X., Xu, F., Zhang, Z., Guo, J., He, Q., Song, L. X., ... & Wu, L. Y. (2021). Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Clinical epigenetics, 13(1), 1-11.

Manjur, A. K., Lempiäinen, J. K., Malinen, M., Varjosalo, M., Palvimo, J. J., & Niskanen, E. A. (2021). BCOR modulates transcriptional activity of a subset of glucocorticoid receptor target genes involved in cell growth and mobility. The Journal of Steroid Biochemistry and Molecular Biology, 210, 105873.

Eckardt, J. N., Stasik, S., Kramer, M., Röllig, C., Krämer, A., Scholl, S., ... & Middeke, J. M. (2021). Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 13(9), 2095.

Bremer, J., Kottke, R., Johann, P. D., von Hoff, K., Brazzola, P., Grotzer, M. A., ... & Gerber, N. U. (2020). A single supratentorial high‐grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival. Pediatric blood & cancer, 67(7), e28384.

Kotov, J. A., Kotov, D. I., Linehan, J. L., Bardwell, V. J., Gearhart, M. D., & Jenkins, M. K. (2019). BCL6 corepressor contributes to Th17 cell formation by inhibiting Th17 fate suppressors. Journal of Experimental Medicine, 216(6), 1450-1464.

Abuhadra, N., Mukherjee, S., Al-Issa, K., Adema, V., Hirsch, C. M., Advani, A., ... & Nazha, A. (2019). BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leukemia & lymphoma, 60(6), 1587-1590.

Kelly, M. J., So, J., Rogers, A. J., Gregory, G., Li, J., Zethoven, M., ... & Kats, L. M. (2019). Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nature communications, 10(1), 1-14.

Tanaka, T., Nakajima-Takagi, Y., Aoyama, K., Tara, S., Oshima, M., Saraya, A., ... & Iwama, A. (2017). Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies. Journal of Experimental Medicine, 214(10), 2901-2913.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-BCOR Recombinant Antibody (CBYY-0453)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare